Fundraising Fox
Alveus Therapeutics
Philadelphia, US · Founded 2023 · Delaware corporation · 34 employees on LinkedIn · 9 known investors
Find your way into Alveus Therapeutics
Sign up to find every way you can get introduced to Alveus Therapeutics
- Your email: who you already know at Alveus Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Alveus Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability. The company uses human genetic data and clinical expertise to select drug targets in the obesity treatment landscape.
Founders & leadership
RK
Raj KannanExecutive
Board
CN
IG
Ivan GergelChief Medical Officer (Interim)Managing Partner and Chief Medical Officer at New Rhein Healthcare Investors, LLC
JV
GI
Garrett IngramBoard director
GP
AN
Ameet NathwaniBoard director
CD
Carlo de NotaristefaniBoard director
Investors · 9
Andera Partnerslisted by Andera PartnersParis
How we know: funding news · press coverage · Not right? Tell us
Avego BioScience Capitallisted by Avego BioScience CapitalAlpharetta
How we know: Avego BioScience Capital's portfolio page · funding news · press coverage · Not right? Tell us
New Rhein Healthcare Investors, LLClisted by New Rhein Healthcare Investors, LLCPhiladelphia
How we know: board seat on SEC Form D · funding news · press coverage · Not right? Tell us
Agent CapitalreportedWaltham
How we know: the VCSheet dataset · Not right? Tell us
Kurma PartnersreportedParis · $162K – $10.8M
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$56.9M disclosed across 1 round · 2025
▶$56.9MraisedJan 2026 · 17 investors · PharmaceuticalsRule 506(b)
▶$56.9MraisedJan 2026 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Claudio NessiDirector
- Ameet NathwaniDirector
- Ivan GergelDirector
- Jan Van de BosscheDirector
- Carlo de NotaristefaniDirector
- Garrett IngramDirector
- Raj KannanExecutive Officer, Director
- Gregory ParekhDirector
- Offering amount
- $110.7M
- Amount sold
- $56.9M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Amicus TherapeuticsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
AgenusAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.
TrisaluslifesciTriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.
Helus PharmaHelus Pharma is a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS conditions such as depression, anxiety, schizophrenia, and bipolar disorder. It focuses on advancing novel treatments for mental health disorders through clinical development and commercialization.
Totus MedicinesTotus Medicines is a biopharmaceutical company developing small molecule drugs to address untreatable diseases by combining approaches in molecular design, structural biology, genetics, and cell biology. The company focuses on oncology and other therapeutic areas for patients with currently incurable conditions.
Vesalius TherapeuticsVesalius Therapeutics develops a computational platform that identifies distinct disease subtypes within common diseases like heart failure, diabetes, and Alzheimer's by analyzing patient data and gene circuits, then uses proprietary cell-based models to discover targeted drug candidates. The company serves patients with prevalent chronic diseases using artificial intelligence, genomics, and patient-derived experimental models.
Arbutus Biopharma CorporationArbutus is a biotechnology company developing therapeutic assets and bringing them to market, with expertise spanning scientific, clinical, operational, and financial development. It focuses on drug development, partnerships, and licensing deals within the biopharma sector.
Companies working in the same space as Alveus Therapeutics.
In the news
Frequently asked questions
- What does Alveus Therapeutics do?
- Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability. The company uses human genetic data and clinical expertise to select drug targets in the obesity treatment landscape.
- Who are Alveus Therapeutics's investors?
- Alveus Therapeutics's investors include Andera Partners, Avego BioScience Capital, Global BioAccess Fund, Jeito Capital, New Rhein Healthcare Investors, LLC, Seroba Life Sciences, Agent Capital, Kurma Partners and 1 more.
- How much funding has Alveus Therapeutics raised?
- Alveus Therapeutics has disclosed $56.9M raised across 1 round.
- Where is Alveus Therapeutics headquartered?
- Alveus Therapeutics is headquartered in Philadelphia, US.